In recent years, the PD - 1/PD-L1 pathway remains a central focus of immunotherapy research, with inhibitors targeting this axis approved for the treatment of several solid tumors, including hepatocellular carcinoma, colorectal cancer, and GC. This evidence concerns the gene CD274 and gastric cancer.